Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Low Grade Glioma: early-phase trial registry
14 of 24 indexed Low Grade Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 14 currently recruiting · #686 of 28,707 conditions by registered trial count
Low Grade Glioma: 24 US clinical trials tracked, 14 recruiting.
Low Grade Glioma is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition low-grade-glioma
OPEN 14 | RECR 58% | LATE 4 | EARLY 15 | RANK #686 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)
Low Grade Glioma lists 14 open slots (58% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Low Grade Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Low Grade Glioma is recruiting above its size-band peers.
14 of 24 indexed trials (58.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Low Grade Glioma research.
National Cancer Institute (NCI) accounts for 4 of 24 trials (16.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Low Grade Glioma enrolment sits around 97 participants.
Median target enrolment is 97 among the 24 trials that report a genuine target (sentinel values excluded). 13 of those (54.2%) plan for fewer than 100 participants.
-
Low Grade Glioma research is mostly interventional.
23 interventional and 1 observational studies make up this index (95.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals
NCT05566795
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
NCT06132685
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
National Cancer Institute (NCI)
NCT04166409
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Day One Biopharmaceuticals
NCT04775485
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
NCT04923126
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Dartmouth-Hitchcock Medical Center
NCT06930846
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
University of California, San Francisco
NCT03948490
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
University of California, San Francisco
NCT07110246
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
NCT04485559
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Children's Hospital of Philadelphia
NCT05555550
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
NCT06712875
A Vaccine Trial for Low Grade Gliomas
James Felker
NCT02358187
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
NCT06104488
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
NCT01089101
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
National Cancer Institute (NCI)
NCT03871257
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
The Hospital for Sick Children
NCT02840409
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
M.D. Anderson Cancer Center
NCT04553757
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
Alicia Lenzen
NCT02455245
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT03749187
Mind-Body Intervention in Glioma Couples
M.D. Anderson Cancer Center
NCT03244995
Proton Radiation Therapy for Gliomas
Massachusetts General Hospital
NCT01358058
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT03718767
Niraparib In Recurrent IDH 1/2 Gliomas
Massachusetts General Hospital
NCT05406700
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 6 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Low Grade Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Low Grade Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Low Grade Glioma page
24 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Low Grade Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Low Grade Glioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Low Grade Glioma condition card totals 24 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.